VK2735 Dosage Chart - Peptide Dosages

VK2735 (10 mg) Dosage Protocol

A dual GIP and GLP-1 receptor agonist from Viking Therapeutics, investigated in phase 2 trials for weight loss — an investigational compound, not an approved drug.

Dual GIP and GLP-1 receptor agonist — the same dual-incretin strategy as tirzepatide, in one peptide.

Once-weekly subcutaneous in VENTURE across 2.5-15 mg arms with weekly titration; presented as research reference, not prescription.

Investigational; phase 2 VENTURE showed up to ~14.7% weight loss at 13 weeks. Not FDA-approved.

Quickstart Highlights

VK2735 is a dual GIP and GLP-1 receptor agonist — a single peptide that activates both incretin receptors, developed by Viking Therapeutics in a once-weekly subcutaneous form and an oral tablet[3]. In the published research it is investigated for appetite suppression and body-weight reduction, and it is widely cross-shopped in the peptide community as a lower-cost tirzepatide-style dual agonist[1].

VK2735 is investigational and not approved by the FDA or any regulator; the figures below reflect early-phase trial conventions and are provided strictly for research and educational reference — not medical advice or a recommendation to self-administer. Grey-market “VK2735” identity and purity are unverifiable.

Mix & measure VK2735 · 10 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Supplies Needed

Everything a documented subcutaneous protocol relies on. Nothing here is exotic — sterile technique and accurate measurement matter far more than any single tool.

Protocol Overview

At 5 mg/mL a single 10 mg vial holds roughly 2 mL of usable solution — enough for several early-titration weeks but only a single dose once you reach a 10 mg weekly level. Plan supply around your target maintenance dose rather than assuming a fixed number of weeks per vial.

Because the dose changes during titration, recalculate your syringe volume at each step rather than reusing a fixed mark.

Dosing Protocol

A reference titration for a 10 mg vial, converted to U-100 units at 5 mg/mL. The VENTURE study also tested a 15 mg weekly arm (the largest weight loss) — that dose exceeds a single 10 mg vial and is noted for completeness only.

Weeks 1–4

2.5 mg (1× weekly)

50 units (0.50 mL)

Weeks 5–8

5 mg (1× weekly)

100 units (1.00 mL)

Weeks 9–12

7.5 mg (1× weekly)

150 units (1.50 mL)

Week 13+

10 mg (1× weekly)

200 units (2.00 mL)

Why VK2735 draws research interest

These are the directions researchers and the peptide community most often explore VK2735 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Weight reduction

Investigated for weight loss — up to ~14.7% over 13 weeks in the phase 2 VENTURE study — through dual GLP-1 and GIP appetite signaling.

Lower-cost dual agonist

Widely cross-shopped as a tirzepatide-style dual incretin agonist; a frequent subject of comparison research.

Oral and injectable forms

Studied in both weekly subcutaneous and oral tablet formulations, with the oral form reaching up to ~12% weight loss in phase 2.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Add 2.0 mL bacteriostatic water to one 10 mg vial → 5 mg/mL (5,000 mcg/mL).

VENTURE arms were 2.5 → 15 mg once weekly; a 10 mg vial supports a 2.5 → 10 mg titration.

Subcutaneous, once weekly on the same day; rotate abdomen / thigh / upper-arm sites.

Investigational (Phase 2 completed) — encouraging mid-stage human data, but no approval and no long-term safety record.

Dosing & Reconstitution Guide

VK2735 is titrated slowly because gastrointestinal tolerability — not peak effect — is the limiting factor. In VENTURE the dose was stepped up over the 13 weeks so the gut could adapt, and GI events fell after the first week.

Standard / Gradual Approach

The phase 2 VENTURE study randomized weekly subcutaneous VK2735 to 2.5, 5, 10 or 15 mg maintenance arms, with most groups starting at 2.5 mg and the 15 mg arm starting at 5 mg before titrating up[1]. A reference titration for a 10 mg vial steps up about every four weeks and holds at any level where side effects are pronounced. Reconstituted at 5 mg/mL, each 2.5 mg increment equals 0.50 mL (50 units on a U-100 syringe).

Reconstitution Steps

Reconstitution is straightforward and identical to other lyophilized peptides.

▪Sanitize: Swab the vial stopper and the bacteriostatic-water vial with fresh alcohol pads and let them dry.

▪Add diluent slowly: Draw 2.0 mL bacteriostatic water and let it run down the inside wall of the vial — do not spray it directly onto the powder.

▪Dissolve gently: Swirl; do not shake. The solution should clear within a minute or two.

▪Store: Label with the date and refrigerate at 2–8 °C; the reconstituted vial holds ~5 mg/mL.

Storage Instructions

Store the lyophilized vial in the freezer or refrigerator away from light until reconstitution.

After reconstitution, keep the vial refrigerated at 2–8 °C and use within the bacteriostatic-water window (commonly cited as up to ~28 days). Discard if the solution becomes cloudy or discolored.

Important Notes

Practical points that keep weekly administration consistent and reduce avoidable side effects.

▪Titrate, don’t rush: In VENTURE, nausea and other GI effects were mostly mild, appeared early, and declined after the first week — holding a step longer is preferable to pushing through[1].

▪Once weekly: The subcutaneous form is dosed once weekly; there is no basis in the research for more frequent subcutaneous dosing or for doubling up after a missed dose.

▪Sterile technique: Fresh U-100 syringe each time, straight into a puncture-proof sharps container afterward.

▪Investigational, unknown long-term safety: VK2735 has phase 2 data only[2]; the incretin drug class carries the GLP-1 caution around personal/family history of medullary thyroid carcinoma or MEN 2 and pancreatitis, and grey-market purity is unverifiable.

How This Works

VK2735 activates both the GLP-1 receptor and the GIP receptor — the same dual-incretin strategy as tirzepatide. GLP-1 signaling enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite in the brain, while adding GIP agonism is thought to further improve nutrient handling and tolerability[3].

Incretin receptor agonists reduce food intake in part by rapidly inhibiting appetite-driving AgRP neurons in the hypothalamus, consistent with the reduced hunger and earlier fullness reported with this class[5]. Viking is developing VK2735 in both weekly subcutaneous and oral tablet forms.

Lifestyle Factors

In the trials that define this class, incretin agents are studied alongside a reduced-calorie diet and increased physical activity — the pharmacology supports behavior change rather than replacing it.

Adequate hydration and protein intake are commonly discussed for managing appetite suppression and preserving lean mass; smaller, slower meals reduce the nausea that comes with delayed gastric emptying.

Potential Benefits & Side Effects

What the phase 2 human literature reports for the investigational compound; this is not equivalent to a prescribed, supervised course, the trial was 13 weeks, and individual outcomes vary.

Reported Effects

▪Weight reduction: In the 13-week VENTURE study, mean weight loss ranged from ~9.1% (2.5 mg) to ~14.7% (15 mg) versus ~1.7% for placebo, with no plateau observed by week 13[1].

▪Dose-dependent response: Weight loss increased with dose across the four subcutaneous arms[2].

▪Appetite & satiety: Reduced hunger and earlier fullness are the expected pharmacology from dual GLP-1 + GIP signaling.

▪Oral form: A separate phase 2 VENTURE-Oral tablet study reported up to ~12% weight loss at 13 weeks[4].

Common Side Effects

▪Gastrointestinal: Nausea was the most common effect (reported in ~43% on VK2735 vs ~20% on placebo), mostly mild, appearing early and declining with continued dosing.

▪Appetite loss & hydration: Strong appetite suppression can reduce food and fluid intake — a practical caution during titration.

▪Class cautions: As an incretin agent it inherits GLP-1-class considerations (gallbladder events, rare pancreatitis, thyroid C-cell contraindication in the class).

▪Unknowns: Long-term safety, durability and rare risks are not yet established for this investigational molecule.

Injection Technique

Subcutaneous injection technique is identical to insulin. Accuracy and site rotation matter more than speed.

Pre-Injection Preparation

▪Wash hands; let the refrigerated vial come toward room temperature to reduce sting.

▪Swab the stopper and injection site; let the alcohol dry fully.

▪Draw your current titration volume into a fresh U-100 syringe and tap out air bubbles.

Injection Procedure

▪Pinch a skinfold at the chosen site (abdomen, outer thigh or back of the upper arm).

▪Insert the needle at 45–90° and inject the solution at a steady, even pace.

▪Withdraw and apply light pressure with a clean swab — do not rub.

Post-Injection Care

▪Drop the used syringe straight into a puncture-proof sharps container.

▪Rotate sites week to week to avoid local irritation or lipohypertrophy.

▪Return the vial to the refrigerator promptly.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for VK2735 (10 mg Vial).

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.

There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.

On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.

Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.

Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.

No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

Related Metabolic & Weight protocols